Acumen to present deeper insights from Phase 1 study of ACU193

Acumen Pharmaceuticals announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AbetaO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer’s Disease conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations. Decades of research have shown that soluble AbetaOs are a highly toxic form of Abeta, based on their propensity to bind to neurons, disrupt synapses and contribute to tau hyper-phosphorylation. ACU193 is the first clinical-stage antibody designed to selectively bind AbetaOs, inhibiting their ability to disrupt synaptic function, while potentially offering improved safety and clinical benefit over existing amyloid-directed therapies. In July of this year, Acumen announced topline results from its INTERCEPT-AD trial which demonstrated that ACU193 was well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1 study in both single and multiple doses in 60 participants with early AD.